Chemotherapy-induced peripheral neuropathy is nerve injury caused by neurotoxic cancer treatment, and it is common: approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, with considerable variability in severity between patients.1 It is often sensory-predominant with pain, and it can lead to long-term morbidity.1 That combination is why management has to look at more than the pain score.
The practical question is not whether you have neuropathy. It is which mechanisms are contributing in your case, and which of them can still be reduced.
Key takeaways
- CIPN is usually sensory-predominant. Burning, numbness and electric sensations are more typical than weakness.1
- The chemotherapy is rarely the only factor. Nutritional and metabolic vulnerabilities can sit underneath it.
- Testing narrows the question. Electrodiagnostic testing (EMG and nerve conduction studies) is performed on site.
- Symptom control is not nerve repair. Medication that turns down the signal has a role, but it is not the whole plan.
- Nothing here is promised as regeneration or cure. The goals are reduced misfire, better function and safer walking.
What is actually injuring the nerve
Neurotoxic chemotherapy agents can injure peripheral nerve fibers directly, and the result usually appears in a distal, sensory-predominant pattern — the feet and hands first, sensation before strength.1 That is the primary mechanism, and it is the one people already know about.
What is less often addressed is the terrain the injury lands on. Nerve fibers depend on a working micro-circulation and on adequate nutritional substrate. When either is compromised before treatment starts, the same dose of the same drug is landing on a less resilient nerve.
Where the overlapping contributors show up
- Metabolic stress, including undiagnosed insulin resistance or diabetes
- Nutritional deficiency, including B12 deficiency and functional B12 deficiency
- Reduced microvascular perfusion to the small vessels that supply nerve tissue
- Pre-existing neuropathy from a driver that was never identified
None of these replaces the chemotherapy as the trigger. They change how much injury a given exposure produces and how much room there is for recovery afterward. Our overview of the hidden drivers of peripheral neuropathy covers the ones that most often go unexamined.
How CIPN is evaluated
Evaluation has one job: turn “I have neuropathy” into a specific description of which fibers are affected and what else is contributing. Without that, treatment is aimed at a category rather than at a mechanism.
What the evaluation includes
- Electrodiagnostic testing (EMG and nerve conduction studies), performed on site, to characterize large-fiber involvement and distribution
- Metabolic and nutritional review, to identify contributors that can be corrected
- VNG balance testing where balance is affected. VNG is a diagnostic test of inner-ear balance function, not a treatment.
Why the exam matters as much as the test
Small nerve fibers carry burning, temperature and pins-and-needles sensation, and they can be substantially injured while routine nerve conduction testing still reads close to normal. A normal study does not mean nothing is wrong. It means the test looked at the fibers it is designed to look at.
Management, in layers
CIPN management works in layers because the nerve is under pressure from more than one direction at a time. Each layer has a defined job, and none of them is presented as the whole answer.
Symptom control
Reducing pain matters for sleep, safety and the ability to stay active. We treat it as volume control rather than as repair, and we are explicit that a lower pain score is not evidence that the nerve has healed.
Light-based and energy-based therapy
Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are used at Regenerve as part of a broader plan aimed at the nerve environment. They are selected when the symptom pattern and the evaluation support them, not applied uniformly.
Metabolic and nutritional care
Where a nutritional or metabolic contributor is identified, correcting it is part of the plan rather than an afterthought. This is also the area with the most consumer marketing attached to it, and the reason we work from your evaluation rather than from a supplement label.
Orthobiologic injections
Orthobiologic injections (PRP and BMAC) are offered in selected situations. We do not present them as a treatment for CIPN.
Safety and function
Reduced protective sensation changes risk in ways that have nothing to do with pain. Daily foot inspection, footwear that fits, and attention to stairs and driving are part of the plan from the first visit.
Where Qutenza fits, and where it does not
Qutenza (capsaicin 8% patch) is indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet.2 Chemotherapy-induced neuropathy is not on that list, so any use in CIPN is off-label and has to be discussed and documented as such.
Where it is used, it is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months. You can read more on our page about the Qutenza capsaicin 8% patch.
When to seek care promptly
- Rapidly progressive numbness or new weakness
- New falls or a sudden change in balance
- A foot wound, skin breakdown, or an injury you did not feel happen
- Pain severe enough to prevent sleep or basic function
Regenerve in the St. Louis region
Regenerve treats peripheral neuropathy for patients across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville. The clinic is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. Call or text (314) 886-5902, or email info@regenerve.com.
Your next step
If chemotherapy is behind your symptoms but you suspect something else is contributing, the free five-question Nerve Damage Score identifies which driver category most likely applies to you, and your answers guide what we evaluate first.
Frequently asked questions
How common is chemotherapy-induced peripheral neuropathy?
Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and the severity varies considerably between patients.1 Our evaluation for nerve symptoms, including on-site electrodiagnostic testing, is described on the neuropathy services page.
Why does my burning feel worse than my test results look?
CIPN is often sensory-predominant with pain,1 and the small nerve fibers that carry burning and temperature sensation are not well captured by routine nerve conduction testing. See small fiber neuropathy symptoms and testing.
Can a vitamin deficiency make chemotherapy nerve symptoms worse?
A nutritional deficiency can sit underneath a chemotherapy-related injury and add to it, which is why the evaluation looks past the obvious trigger. See functional B12 deficiency and neuropathy.
Does Qutenza [Capsaicin 8% Patch] treat CIPN?
Qutenza [Capsaicin 8% Patch] is indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet.2 Use for chemotherapy-induced neuropathy is off-label and would need to be discussed with a clinician. One of the two approved indications is covered in our article on postherpetic neuralgia and shingles nerve pain.
Sources
- Staff NP, Grisold A, Grisold W, Windebank AJ, “Chemotherapy-induced peripheral neuropathy: A current review,” Annals of Neurology, 2017;81(6):772-781, https://pmc.ncbi.nlm.nih.gov/articles/PMC5656281/
- U.S. Food and Drug Administration, “QUTENZA (capsaicin) 8% topical system — prescribing information,” label effective July 7, 2026, via DailyMed, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad93-4f15-bb38-5da76a71c735
- Rahman N, Sukumar J, Lustberg MB, “Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments,” Annals of Palliative Medicine, 2025, https://apm.amegroups.org/article/view/136218/html
- Batash R, Asna N, Ali SH, Charkovsky T, Asali M, Pelles S, Schaffer M, “Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients — A New Promise? Preliminary Results,” 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12562927/